Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Amgen Inc.
Amgen Inc. News
Amgen Inc. Quantitative Score
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Amgen Inc. Earnings & Revenue
Amgen Inc. Financials
Table Compare
Compare AMGN metrics with: | |||
|---|---|---|---|
Earnings & Growth | AMGN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | AMGN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | AMGN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | AMGN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Amgen Inc. Income
Amgen Inc. Balance Sheet
Amgen Inc. Cash Flow
Amgen Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Amgen Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 9.2600 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2025-06-06 | 2.38 | Quarterly |
| 2025-03-07 | 2.38 | Quarterly |
| 2024-12-09 | 2.25 | Quarterly |
| 2024-09-06 | 2.25 | Quarterly |
| 2024-06-07 | 2.25 | Quarterly |
Amgen Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Amgen Inc. Executives
| Name | Role |
|---|---|
| Mr. Robert A. Bradway | Chairman, Chief Executive Officer & President |
| Dr. James E. Bradner M.D. | Executive Vice President of Research & Development |
| Dr. David M. Reese M.D. | Executive Vice President & Chief Technology Officer |
| Mr. Murdo Gordon | Executive Vice President of Global Commercial Operations |
| Mr. Peter H. Griffith | Executive Vice President & Chief Financial Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Robert A. Bradway | Chairman, Chief Executive Officer & President | Male | 1963 | 6.43M |
| Dr. James E. Bradner M.D. | Executive Vice President of Research & Development | 1972 | 4.1M | |
| Dr. David M. Reese M.D. | Executive Vice President & Chief Technology Officer | 1963 | 3.33M | |
| Mr. Murdo Gordon | Executive Vice President of Global Commercial Operations | Male | 1967 | 3.17M |
| Mr. Peter H. Griffith | Executive Vice President & Chief Financial Officer | Male | 1959 | 3.01M |
Amgen Inc. Insider Trades
| Date | 17 Mar |
| Name | Santos Esteban |
| Role | EVP, Operations |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 3393 |
| Date | 17 Mar |
| Name | REESE DAVID M |
| Role | EVP & Chief Technology Officer |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 3635 |
| Date | 17 Mar |
| Name | Miller Derek |
| Role | SVP, Human Resources |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 930 |
| Date | 17 Mar |
| Name | Khosla Rachna |
| Role | SVP, Business Development |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 489 |
| Date | 17 Mar |
| Name | Grygiel Nancy A. |
| Role | SVP & CCO |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 524 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 17 Mar | Santos Esteban | EVP, Operations | Disposed | F-InKind | 3393 |
| 17 Mar | REESE DAVID M | EVP & Chief Technology Officer | Disposed | F-InKind | 3635 |
| 17 Mar | Miller Derek | SVP, Human Resources | Disposed | F-InKind | 930 |
| 17 Mar | Khosla Rachna | SVP, Business Development | Disposed | F-InKind | 489 |
| 17 Mar | Grygiel Nancy A. | SVP & CCO | Disposed | F-InKind | 524 |